Skip to main content
NCBI home page
Frontiers in Cellular Neuroscience logoLink to Frontiers in Cellular Neuroscience
. 2024 Apr 5;18:1384085. doi: 10.3389/fncel.2024.1384085

Knockdown of tgfb1a partially improves ALS phenotype in a transient zebrafish model

David Gonzalez 1,2,3,*, Xiomara Cuenca 2, Miguel L Allende 3
PMCID: PMC11032012  PMID: 38644973

Abstract

Amyotrophic lateral sclerosis (ALS) corresponds to a neurodegenerative disorder marked by the progressive degeneration of both upper and lower motor neurons located in the brain, brainstem, and spinal cord. ALS can be broadly categorized into two main types: sporadic ALS (sALS), which constitutes approximately 90% of all cases, and familial ALS (fALS), which represents the remaining 10% of cases. Transforming growth factor type-β (TGF-β) is a cytokine involved in various cellular processes and pathological contexts, including inflammation and fibrosis. Elevated levels of TGF-β have been observed in the plasma and cerebrospinal fluid (CSF) of both ALS patients and mouse models. In this perspective, we explore the impact of the TGF-β signaling pathway using a transient zebrafish model for ALS. Our findings reveal that the knockdown of tgfb1a lead to a partial prevention of motor axon abnormalities and locomotor deficits in a transient ALS zebrafish model at 48 h post-fertilization (hpf). In this context, we delve into the proposed distinct roles of TGF-β in the progression of ALS. Indeed, some evidence suggests a dual role for TGF-β in ALS progression. Initially, it seems to exert a neuroprotective effect in the early stages, but paradoxically, it may contribute to disease progression in later stages. Consequently, we suggest that the TGF-β signaling pathway emerges as an attractive therapeutic target for treating ALS. Nevertheless, further research is crucial to comprehensively understand the nuanced role of TGF-β in the pathological context.

Keywords: amyotrophic lateral sclerosis, transforming growth factor type β, danio rerio, zebrafish, motor neuron, neurodegenerative disease

1 Introduction

Amyotrophic lateral sclerosis (ALS) corresponds to a neurodegenerative disease affecting upper (UMNs) and lower motor neurons (LMNs) from brain, brainstem and spinal cord. The degeneration of both UMNs and LMNs leads to muscle wasting, fibrosis and paralysis (Pansarasa et al., 2014; Mancuso and Navarro, 2015). ALS patients usually die within 3–5 years from symptoms onset, mainly because of respiratory failures (Taylor et al., 2016). The identification of mutations in the SOD1 gene in 1993 marked a significant breakthrough in ALS research (Rosen et al., 1993), and 1 year later the first ALS mouse model was generated, carrying the SOD1 gene with a glycine-to-alanine substitution at position 93 (Gurney et al., 1994). Approximately 90% of ALS cases manifest as the sporadic form (sALS), while the remaining 10% of cases exhibit a genetic component associated and are referred to as familial ALS (fALS) (Riva et al., 2016; Mejzini et al., 2019). As of now, mutations in several genes, such as SOD1, TAR DNA-binding protein 43 (TARDBP) and C9ORF72, have been linked to ALS (Renton et al., 2014; Taylor et al., 2016). To date, only two drugs, riluzole and edaravone, have received approval in certain countries for the treatment of ALS. Riluzole, which acts as an anti-glutamate agent, has demonstrated the ability to improve survival of ALS patients in clinical trials. However, it remains uncertain whether this extension of survival applies uniformly across various stages of the disease (Fang et al., 2018; Andrews et al., 2020; Feldman et al., 2022). Conversely, edaravone, functioning as an antioxidant, has shown the capacity to slow disease progression in clinical trials. Nevertheless, uncertainties persist regarding its applicability to a broader ALS patient population, and questions about its safety and benefits have arisen (Lunetta et al., 2020; Shefner et al., 2020; Feldman et al., 2022; Witzel et al., 2022). Hence, there remains an urgent need to identify new therapeutic targets for the treatment of neurodegenerative diseases, such as ALS.

Transforming growth factor type β (TGF-β) is a widely expressed cytokine that plays pivotal roles in development, homeostasis (Vander Ark et al., 2018) and pathological conditions such as cancer and fibrosis (Peng et al., 2022). In mammals, three isoforms have been identified: TGF-β1, TGF-β2 and TGF-β3, however, the TGF-β superfamily comprises other ligands such as activins, myostatin, Nodal, among others (David and Massagué, 2018). The Smad-dependent TGF-β pathway, also known as canonical pathway, involves the phosphorylation of Smad2/3 complex by the TGF-β receptor I kinase. Afterward, phosphorylated Smad2/3 complex binds to Smad4 and translocates into the nucleus (Massagué, 1998; Leask and Abraham, 2004). In this regard, studies have demonstrated increased levels of TGF-β1 in both the serum and cerebrospinal fluid (CSF) of ALS patients (Houi et al., 2002; Iłz̈ecka et al., 2002) and in an ALS mouse model (Zubiri et al., 2018). Furthermore, increased expression of Tgfb1 mRNA has been observed in skeletal muscle of ALS mice (Galbiati et al., 2012) and elevated levels of TGF-β cytokine and its canonical downstream mediator, Smad3, have been correlated with muscle fibrosis in these mice (Gonzalez et al., 2017). More recently, the TGFB1 mRNA has been found to be increased in skeletal muscle of both male and female ALS patients (Meroni et al., 2019). Interestingly, the upregulation of astrocyte-derived TGF-β1 has also been identified in the spinal cord of symptomatic ALS mice, and its pharmacological inhibition has been shown to extend the survival of ALS mice (Endo et al., 2015; Endo and Yamanaka, 2015). A previous study demonstrated that TGF-β1 immunoreactivity is present in the meninges and choroid plexus in the brains of adult rats, as well as in the connective tissue of peripheral nerves and ganglia. However, the authors did not detect expression of TGF-β1 within neurons or glia (Unsicker et al., 1991). Nonetheless, high levels of TGF-β1 mRNA have been identified in several brain areas, including the cerebral cortex, hippocampus, amygdala, hypothalamic paraventricular nucleus, and motor neurons (Vincze et al., 2010). Another study revealed that type I and type II TGF-β receptors are expressed in meningeal fibroblasts following injury. Interestingly, reactive astrocytes did not exhibit strong expression of TGF-β receptors, suggesting that fibroblasts are more likely to respond to TGF-β1 after injury in the central nervous system (Komuta et al., 2010). While there have been some efforts to elucidate the precise role of TGF-β1 signaling in the progression of ALS, several questions remain open.

Zebrafish is emerging as an attractive model for studying neurodegenerative diseases due to its high conservation of genes linked to ALS, genes involved in the development and maintenance of the nervous system, cost-effectiveness, and suitability for high-throughput screening, attributes that distinguish it from other mammalian models (Bandmann and Burton, 2010; Becker and Rinkwitz, 2012). Additionally, the optical transparency of zebrafish embryos is a significant advantage in the context of ALS (Lieschke and Currie, 2007; Babin et al., 2014; Oliveira et al., 2023). This property enables in vivo whole-mount microscopy, allowing researchers to visualize motor neurons in real-time. Zebrafish also share structural neuroanatomical and neurophysiological similarities with humans, making them highly relevant for studying ALS. Furthermore, ALS-related locomotor tests can be performed in larvae, such as touch-evoked responses and spontaneous movement assays. These behavioral assays provide valuable insights into motor function, which facilitates the evaluation of potential therapeutic interventions (Babin et al., 2014; Oliveira et al., 2023).

In this perspective, we sought to explore the potential involvement of TGF-β1 in the progression of ALS, using a transient zebrafish model expressing the mutated hSOD1. We also discussed the recent findings regarding the role of TGF-β signaling pathway in ALS progression. Lastly, we offered insights into the future directions and discussed the therapeutic potential of targeting TGF-β1 as a promising avenue for ALS.

2 Partial prevention of motor axon abnormalities through tgfb1a knockdown in a transient ALS zebrafish model

We employed a transient ALS zebrafish model, which consists in microinjecting the human SOD1 mRNA carrying the G93A mutation (hereafter referred to as hSOD1G93A). This well-established model has been extensively used to study ALS in zebrafish (Lemmens et al., 2007; Robinson et al., 2019), since it is valued for its cost-effectiveness and rapid generation of outcomes in zebrafish studies. In order to assess the potential involvement of the TGF-β signaling pathway in the progression of ALS in this zebrafish model, we knocked down the tgfb1a by co-microinjecting hSOD1G93A mRNA along with an antisense morpholino (MO) targeting tgfb1a mRNA (CAGCACCAAGCAAACCAACCTCATA; GeneTools) at the one cell stage (Supplementary File 1). Briefly, we conducted in vitro synthesis of hSOD1WT/G93A mRNAs from plasmids pcDNA3.1(+)SOD1WT (Addgene #26397) and pcDNA3.1(+)SOD1G93A (Addgene #26401) using a mMESSAGE mMACHINE® T7 (Ambion #AM1344) and subsequently purified the mRNAs using the MEGAClear™ kit (Ambion, #AM1908).

We analyzed the zebrafish motor axons at 48 h post-fertilization (hpf) by immunofluorescence, using a Znp-1 antibody (DSHB Cat# znp-1, RRID:AB_2315626), across the following experimental groups: non-injected, hSOD1WT mRNA, hSOD1G93A mRNA, tgfb1a-MO, and hSOD1G93A mRNA + tgfb1a-MO. As depicted in the representative images from Figures 1A, B, we observed a significant reduction of both axon length and total length, in hSOD1G93A-expressing embryos (171.1 and 340.4 μm), in comparison to non-injected (205.8 and 518 μm) and hSOD1WT-expressing embryos (208.9 and 508 μm). While no significant increase in axon length (180.9 μm) was noted in hSOD1G93A-expressing embryos co-microinjected with a tgfb1-MO (Figure 1C), we found a significant increase in axon total length (473 μm), as illustrated in Figure 1D. These results suggest that the knockdown of tgfb1a leads to a partial prevention of motor axon abnormalities in a transient ALS zebrafish model.

FIGURE 1.

FIGURE 1

Open in a new tab

Knockdown of tgfb1a partially prevents motor axon abnormalities in hSOD1G93A-expressing zebrafish embryos. (A,B) Zebrafish embryos at the one-cell stage were subjected to microinjection with hSOD1WT mRNA (n = 10), hSOD1G93A mRNA (n = 12), tgfb1a-MO (n = 8), or co-microinjected with hSOD1G93A mRNA and hSOD1G93A mRNA (n = 9). Additionally, a non-injected group (n = 12) served as a control. At 48 hpf, the embryos were immunostained with Znp-1 antibody, and motor axon morphology was analyzed using ImageJ software with NeuronJ plugin, as previously described (Meijering et al., 2004; Robinson et al., 2019). The graphs depict quantifications of (C) axon length and (D) total length of motor axons (5–7 motor axons per embryo). Box and whisker plots represent the 25th and 75th percentiles, with medians represented by bisecting lines and means denoted by “+.” Whiskers indicate extreme values. Statistical differences were assessed using one-way ANOVA and Tukey’s multiple comparison test, *p < 0.05, **p < 0.01, n.s.: not significant. Scale bar: 100 μm.

3 Partial prevention of locomotor deficits through tgfb1a knockdown in a transient ALS zebrafish model

Since we found a partial prevention of motor axon abnormalities in tgfb1a knocked down hSOD1G93A-expressing zebrafish embryos, we wanted to evaluate the locomotor function in these experimental groups. Briefly, we performed a touch-evoked response assay, in which 48 hpf embryos were subjected to gentle mechanical stimulation, and their swimming behavior was subsequently scored. The categorized swimming behavior included normal swimming, looping swimming, pinwheel swimming, or motionless, depending on the embryos’ reactions to the stimulation. We found that the majority of the non-injected and hSOD1WT-expressing embryos exhibited normal swimming behavior, accounting for 71 and 66.7%, respectively. In contrast, only 29.4% of hSOD1G93A-expressing embryos showed normal swimming behavior. Notably, other types of swimming patterns emerged in this group, including moderate swimming (35.3%), looping swimming (17.6%), pinwheel swimming (11.8%) and motionless (5.9%), as shown in Figure 2A. Importantly, we observed an increase in normal swimming behavior (41.7%) in hSOD1G93A-expressing embryos co-microinjected with tgfb1-MO compared to hSOD1G93A-expressing embryos. Concurrently, we found a reduction in moderate swimming (30.6%), looping swimming (11.1%), pinwheel swimming (8.3%), although 8.3% of the embryos displayed motionless behavior. Zebrafish embryos microinjected with tgfb1a-MO did not exhibit significant variations compared to non-injected and hSOD1WT-expressing embryos.

FIGURE 2.

FIGURE 2

Open in a new tab

Knockdown of tgfb1a partially prevents locomotor deficits in hSOD1G93A-expressing zebrafish larvae. At 48 hpf, zebrafish embryos from the following experimental groups: non-injected (n = 14), hSOD1WT mRNA (n = 14), hSOD1G93A mRNA (n = 19), tgfb1a-MO (n = 11) and hSOD1G93A mRNA + tgfb1a-MO (n = 11), underwent a (A) touch-evoked response assay, involving slight mechanical stimulation with subsequent evaluation and scoring of swimming behavior as normal swimming, looping swimming, pinwheel swimming or motionless. The graph depicts the percentage of each swimming type for the different experimental conditions. (B) Spontaneous locomotor activity was assessed in the same experimental groups as in A. At 48 hpf, each zebrafish embryo was placed into a single well of a 96-well plate, and their spontaneous locomotor activity was measured over 1 h using the automated Microtracker system, as previously described (Simonetta and Golombek, 2007; Paredes-Zúñiga et al., 2019). The values in B correspond to the mean ± SEM. Statistical differences were assessed using one-way ANOVA and Tukey’s multiple comparison test, ***p < 0.001.

Furthermore, we assessed the spontaneous locomotor activity of the aforementioned experimental groups using the Microtracker system (Phylumtech), as previously described (Simonetta and Golombek, 2007; Paredes-Zúñiga et al., 2019). In brief, 48 hpf zebrafish embryos were individually placed into a well of a 96-well plate, and their spontaneous locomotor activity was measured over the course of 1 h. Figure 2B shows that hSOD1G93A-expressing embryos excited reduced spontaneous activity (9.72 bins/hr) in comparison to non-injected (30.71 bins/hr) and hSOD1WT-expressing embryos (23.5 bins/hr). Interestingly, hSOD1G93A-expressing embryos co-microinjected with tgfb1-MO showed an increase in spontaneous locomotor activity (22.5 bins/hr) when compared to their hSOD1G93A-expressing counterparts. Zebrafish embryos microinjected with tgfb1a-MO did not exhibit significant variations in spontaneous locomotor activity compared to non-injected and hSOD1WT-expressing embryos. These findings suggest that knockdown of tgfb1a results in a partial prevention of locomotor deficits in hSOD1G93A-expressing zebrafish embryos.

4 Discussion

Our findings show that the knockdown of tgfb1 partially prevented motor axon abnormalities and partially enhances locomotor function in hSOD1G93A-expressing embryos at 48 hpf. In this regard, some evidence exists of the role of TGF-β signaling pathway in ALS disease. As mentioned earlier, elevated levels of TGF-β1 have been detected in serum and CSF of both ALS patients and animal models (Houi et al., 2002; Iłz̈ecka et al., 2002; Peters et al., 2017; Zubiri et al., 2018). More recently, a study showed that R-loops, structures formed of three-stranded nucleic acid, are depleted in ALS patients carrying a mutation in the senataxin (SETX) gene, affecting gene expression including the expression of BAMBI, a negative regulator of TGF-β and ultimately, leading to TGF-β signaling pathway activation (Grunseich et al., 2018). Another study has shown reduced levels of Tgfb1 mRNA in the spinal cord of hSOD1G93A mice at pre-symptomatic stages (Meroni et al., 2019). Thus, given the accumulating evidence regarding the involvement of the TGF-β signaling pathway in ALS disease progression, it has been recently proposed that decreased levels of TGF-β in the early stages of ALS may diminish its neuroprotective activity, increasing the glutamate-induced excitotoxicity. Conversely, elevated TGF-β levels in later stages of ALS are thought to contribute to heightened microglial activation, neuromuscular junction (NMJ) dismantling, and subsequent skeletal muscle atrophy (Galbiati et al., 2020).

While it is challenging to generalize this assertion to every animal model, our observation of improved motor axon morphology in the transient ALS zebrafish model at an embryonic stage (48 hpf) suggests a potential role of TGF-β in this context. It is important to note that our current approach may not distinctly delineate between early and late stages of ALS. Embryonic zebrafish models have certain limitations, especially when modeling adult-onset diseases such as ALS. However, the phenomenon of disease-acceleration observed in zebrafish models is frequently employed as a strategy to enhance tractability at the expense of construct validity (Oliveira et al., 2023). Furthermore, distinguishing between alterations in developmental processes and neurodegeneration presents a challenge (Babin et al., 2014). Thus, using live imaging microscopy in transient and transgenic ALS zebrafish models could offer valuable insights into addressing this question. In this context, zebrafish models provide a convenient and cost-effective experimental model for drug screening, which requires subsequent validation in mammalian models. Further investigations, including those employing transgenic ALS zebrafish models, could provide a more comprehensive understanding of the temporal dynamics of TGF-β involvement in ALS disease progression. A related study has shown that tgfb1a gene is expressed in the posterior lateral line (pLL) primordium, a mechanosensory system involved in prey detection and avoidance (Coombs and Van Netten, 2005; Xing et al., 2015). In this study, the knockdown of tgfb1a resulted in reduced neuromast number, migration and deposition, indicating that tgfb1a gene essential pLL development (Xing et al., 2015). More recently, it has been shown that inhibition of TGF-β signaling perturbs perineurial glia maturation, a cell type that ensheaths axon-Schwann cell bundles and forms the blood-nerve-barrier (Kucenas, 2015; Morris et al., 2017). Interestingly, another study from the same laboratory has shown that TGF-β signaling pathway, through its downstream mediator connective tissue growth factor-a (ctgfa), is involved in forming the bridge between proximal and distal stumps after motor nerve injury in zebrafish embryos (Arena et al., 2022). However, to date, there is no specific evidence demonstrating the role of TGF-β in ALS zebrafish models. In our transient ALS zebrafish model, TGF-β appears to exert a detrimental effect rather than its neuroprotective role, since its knockdown partially prevents the ALS phenotype. TGF-β activation triggers proinflammatory and neurotoxic responses while promoting extracellular matrix (ECM) deposition, which can lead to in neurodegeneration (Peters et al., 2017).

Recently, a study has found that induced pluripotent stem cell (iPSCs)-derived motor neurons from ALS patients carrying mutations in the C9ORF72 gene show augmented expression of ECM genes and TGF-β targets. However, they did not find the same pattern in iPSCs-derived motor neurons from ALS patients carrying mutations in the SOD1 gene (Wong and Venkatachalam, 2019). These findings suggest that TGF-β signaling activation in ALS may also be dependent on gene mutations.

The effect of TGF-β can vary depending on the tissue. It is well known that increased levels of TGF-β in skeletal muscle hamper myofiber regeneration and promote deposition of extracellular matrix components (ECM), which leads to a scar formation known as fibrosis in other muscular disorders (Wynn, 2008; Walton et al., 2017; Ismaeel et al., 2019). In this regard, it has been shown that skeletal muscles of symptomatic ALS mice exhibit enhanced canonical TGF-β signaling, which correlates with ECM deposition and induction of fibro/adipogenic progenitors (FAPs) markers, a cell type responsible for secreting ECM (Gonzalez et al., 2017). Moreover, some studies show that TGF-β1-3 expression are increased in muscles of ALS patients (Pradat et al., 2011; Si et al., 2015; Meroni et al., 2019). Thus, it would be interesting to knockdown tgf1b in transgenic ALS zebrafish in order to evaluate the ECM deposition within skeletal muscle and how it affects muscle function.

Efforts have been made to assess the therapeutic potential of targeting TGF-β signaling pathway in ALS mice. It has been shown that intraperitoneal injection of recombinant human TGF-β2 improves the locomotor performance in ALS mice; however, it did not prevent the degeneration of motor neurons and disease progression (Day et al., 2005). Conversely, pharmacological inhibition of the TGF-β signaling pathway using the SB-431542 inhibitor has been demonstrated to increase lifespan in ALS mice (Endo et al., 2015). While intriguing, these paradoxical observations reveal the complex roles of TGF-β signaling pathway in the context of ALS. Endo et al. (2015) also showed that astrocytes upregulate TGF-β1 in the lumbar section of the spinal cord from ALS mice and more importantly, the excess of astrocyte-derived TGF-β1 accelerates the progression of the disease. They hypothesize that adverse effects on motor neurons by inhibiting TGF-β may be minimal. However, they propose that modulation of TGF-β signaling in a cell type-specific manner, i.e., inducing TGF-β signaling pathway in motor neuron to promote its neuroprotective effects and, inhibiting TGF-β in astrocytes to reduce neuroinflammation (Endo et al., 2015). On the other hand, the therapeutic potential of other member of the TGF-β superfamily have also been explored in ALS animal models. The inhibition of myostatin, which is a negative regulator of muscle growth, have been shown to reduce muscle atrophy and improve muscle strength in ALS mice and rats. However, despite these beneficial effects on muscle function, myostatin inhibition did not extend the lifespan of ALS rodents (Holzbaur et al., 2006; Morrison et al., 2009). This suggests that while targeting myostatin may ameliorate certain aspects of ALS disease, it may not be sufficient to prolong survival of patients.

In this scenario, it is plausible to consider that inhibition of the TGF-β signaling pathway could be potentially reducing early neuroinflammation and preventing locomotor deficits in our zebrafish model. However, more studies are needed in order to comprehend the precise mechanism by which TGF-β inhibition contributes to the amelioration of the disease. Peters et al. (2017) proposed that sustained upregulation of TGF-β signaling contributes to motor neuron degeneration through various mechanisms. This includes activating a proinflammatory and neurotoxic response, arresting neuronal stem cells, and promoting fibrotic activity (Peters et al., 2017).

Thus, investigating the effects of pharmacological inhibition of the TGF-β signaling pathway across various stages of the disease using a transgenic ALS zebrafish model could shed light onto the involvement of TGF-β in ALS pathogenesis. Such studies could elucidate the temporal dynamics of TGF-β signaling and its impact on ALS disease progression. Understanding how TGF-β signaling varies over time and its specific impact on different stages of ALS disease may reveal opportunities for therapeutic interventions. Lastly, by elucidating these dynamics, researchers will be able to develop more targeted and effective TGF-β-directed therapies for treating ALS patients.

5 Concluding remarks and future directions

In this perspective, we showed that the knockdown of tgfb1 partially enhances the morphology of motor axons and improves locomotor function in hSOD1G93A-expressing embryos at 48 hpf. These findings contribute additional evidence supporting the therapeutic potential of modulating TGF-β signaling pathway to ameliorate the progression of ALS. Certainly, further studies are crucial to fully unravel the involvement of TGF-β signaling pathway in ALS. Our current findings raise several questions: (i) What would be the effect of inhibiting TGF-β in later stages of a transgenic ALS zebrafish model? (ii) What are the specific contributions of the TGF-β derived from motor neurons, glia, or skeletal muscle in this zebrafish model? (iii) Is this effect mediated by canonical or non-canonical downstream mediators? The current evidence emphasizes distinct roles of TGF-β depending on the tissue and the stage of the disease (Galbiati et al., 2020), underscoring the need for a more delicate understanding through additional research. Hence, the modulation of the TGF-β signaling pathway is emerging as an appealing therapeutic approach for treating ALS, although more studies are needed to fully comprehend its specific contribution to disease progression.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was approved by the Animal Use and Care Committee of the University of Chile. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

DG: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing. XC: Formal analysis, Investigation, Writing – review and editing. MA: Funding acquisition, Resources, Supervision, Writing – review and editing.

Funding Statement

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the ANID-Millennium Science Initiative Program-ICN2021_044 to MA and the ANID/Fondecyt postdoctoral fellowship 3200061 to DG.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fncel.2024.1384085/full#supplementary-material

Table_1.docx (15.7KB, docx)

References

  1. Andrews J. A., Jackson C. E., Heiman-Patterson T. D., Bettica P., Brooks B. R., Pioro E. P. (2020). Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 21 509–518. 10.1080/21678421.2020.1771734 [DOI] [PubMed] [Google Scholar]
  2. Arena K. A., Zhu Y., Kucenas S. (2022). Transforming growth factor-beta signaling modulates perineurial glial bridging following peripheral spinal motor nerve injury in zebrafish. Glia 70 1826–1849. 10.1002/glia.24220 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Babin P. J., Goizet C., Raldúa D. (2014). Zebrafish models of human motor neuron diseases: Advantages and limitations. Prog. Neurobiol. 118 36–58. 10.1016/j.pneurobio.2014.03.001 [DOI] [PubMed] [Google Scholar]
  4. Bandmann O., Burton E. A. (2010). Genetic zebrafish models of neurodegenerative diseases. Neurobiol. Dis. 40 58–65. 10.1016/j.nbd.2010.05.017 [DOI] [PubMed] [Google Scholar]
  5. Becker T. S., Rinkwitz S. (2012). Zebrafish as a genomics model for human neurological and polygenic disorders. Dev. Neurobiol. 72 415–428. 10.1002/dneu.20888 [DOI] [PubMed] [Google Scholar]
  6. Coombs S., Van Netten S. (2005). The hydrodynamics and structural mechanics of the lateral line system. Fish Physiol. 23 103–139. 10.1016/S1546-5098(05)23004-2 [DOI] [Google Scholar]
  7. David C. J., Massagué J. (2018). Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19 419–435. 10.1038/s41580-018-0007-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Day W. A., Koishi K., Nukuda H., McLennan I. S. (2005). Transforming growth factor-beta 2 causes an acute improvement in the motor performance of transgenic ALS mice. Neurobiol. Dis. 19 323–330. 10.1016/j.nbd.2005.01.010 [DOI] [PubMed] [Google Scholar]
  9. Endo F., Komine O., Fujimori-Tonou N., Katsuno M., Jin S., Watanabe S., et al. (2015). Astrocyte-Derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T Cells. Cell Rep. 11 592–604. 10.1016/j.celrep.2015.03.053 [DOI] [PubMed] [Google Scholar]
  10. Endo F., Yamanaka K. (2015). Astrocytic tgf-β1: Detrimental factor in ALS. Oncotarget 6 15728–15729. 10.18632/oncotarget.4786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fang T., Al Khleifat A., Meurgey J. H., Jones A., Leigh P. N., Bensimon G., et al. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17 416–422. 10.1016/S1474-4422(18)30054-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feldman E. L., Goutman S. A., Petri S., Mazzini L., Savelieff M. G., Shaw P. J., et al. (2022). Amyotrophic lateral sclerosis. Lancet 400 1363–1380. 10.1016/S0140-6736(22)01272-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Galbiati M., Crippa V., Rusmini P., Cristofani R., Messi E., Piccolella M., et al. (2020). Multiple roles of transforming growth factor beta in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 21 1–17. 10.3390/ijms21124291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Galbiati M., Onesto E., Zito A., Crippa V., Rusmini P., Mariotti R., et al. (2012). The anabolic/androgenic steroid nandrolone exacerbates gene expression modifications induced by mutant SOD1 in muscles of mice models of amyotrophic lateral sclerosis. Pharmacol. Res. 65 221–230. 10.1016/j.phrs.2011.12.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gonzalez D., Contreras O., Rebolledo D. L., Espinoza J. P., Van Zundert B., Brandan E. (2017). ALS skeletal muscle shows enhanced TGF-β signaling, fibrosis and induction of fibro/adipogenic progenitor markers. PLoS One 12:e0177649. 10.1371/journal.pone.0177649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Grunseich C., Wang I. X., Watts J. A., Burdick J. T., Guber R. D., Zhu Z., et al. (2018). Senataxin mutation reveals how r-loops promote transcription by blocking DNA methylation at gene promoters. Mol. Cell 69 426–437.e7. 10.1016/j.molcel.2017.12.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., et al. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 1772–1775. 10.1126/science.8209258 [DOI] [PubMed] [Google Scholar]
  18. Holzbaur E. L. F., Howland D. S., Weber N., Wallace K., She Y., Kwak S., et al. (2006). Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol. Dis. 23 697–707. 10.1016/j.nbd.2006.05.009 [DOI] [PubMed] [Google Scholar]
  19. Houi K., Kobayashi T., Kato S., Mochio S., Inoue K. (2002). Increased plasma TGF-β1 in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 106 299–301. 10.1034/j.1600-0404.2002.01301.x [DOI] [PubMed] [Google Scholar]
  20. Iłz̈ecka J., Stelmasiak Z., Dobosz B. (2002). Transforming growth factor-beta 1 (TGF-beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 20 239–243. 10.1006/cyto.2002.2005 [DOI] [PubMed] [Google Scholar]
  21. Ismaeel A., Kim J. S., Kirk J. S., Smith R. S., Bohannon W. T., Koutakis P. (2019). Role of transforming growth factor-β in skeletal muscle fibrosis: A review. Int. J. Mol. Sci. 20:2446. 10.3390/ijms20102446 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Komuta Y., Teng X., Yanagisawa H., Sango K., Kawamura K., Kawano H. (2010). Expression of transforming growth factor-β receptors in meningeal fibroblasts of the injured mouse brain. Cell. Mol. Neurobiol. 30 101–111. 10.1007/s10571-009-9435-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kucenas S. (2015). Perineurial glia. Cold Spring Harb. Perspect. Biol. 7 1–14. 10.1101/cshperspect.a020511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Leask A., Abraham D. J. (2004). TGF−β signaling and the fibrotic response. FASEB J. 18 816–827. 10.1096/fj.03-1273rev [DOI] [PubMed] [Google Scholar]
  25. Lemmens R., Van Hoecke A., Hersmus N., Geelen V., D’Hollander I., Thijs V., et al. (2007). Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum. Mol. Genet. 16 2359–2365. 10.1093/hmg/ddm193 [DOI] [PubMed] [Google Scholar]
  26. Lieschke G. J., Currie P. D. (2007). Animal models of human disease: Zebrafish swim into view. Nat. Rev. Genet. 8 353–367. 10.1038/nrg2091 [DOI] [PubMed] [Google Scholar]
  27. Lunetta C., Moglia C., Lizio A., Caponnetto C., Dubbioso R., Giannini F., et al. (2020). The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J. Neurol. 267 3258–3267. 10.1007/s00415-020-09993-z [DOI] [PubMed] [Google Scholar]
  28. Mancuso R., Navarro X. (2015). Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog. Neurobiol. 133 1–26. 10.1016/j.pneurobio.2015.07.004 [DOI] [PubMed] [Google Scholar]
  29. Massagué J. (1998). TGF-β signal transduction. Annu. Rev. Biochem. 67 753–791. 10.1146/annurev.biochem.67.1.753 [DOI] [PubMed] [Google Scholar]
  30. Meijering E., Jacob M., Sarria J. C. F., Steiner P., Hirling H., Unser M. (2004). Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytom. Part A 58 167–176. 10.1002/cyto.a.20022 [DOI] [PubMed] [Google Scholar]
  31. Mejzini R., Flynn L. L., Pitout I. L., Fletcher S., Wilton S. D., Akkari P. A. (2019). ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 13:1310. 10.3389/fnins.2019.01310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Meroni M., Crippa V., Cristofani R., Rusmini P., Cicardi M. E., Messi E., et al. (2019). Transforming growth factor beta 1 signaling is altered in the spinal cord and muscle of amyotrophic lateral sclerosis mice and patients. Neurobiol. Aging 82 48–59. 10.1016/j.neurobiolaging.2019.07.001 [DOI] [PubMed] [Google Scholar]
  33. Morris A. D., Lewis G. M., Kucenas S. (2017). Perineurial glial plasticity and the role of TGF-β in the development of the blood–nerve barrier. J. Neurosci. 37 4790–4807. 10.1523/jneurosci.2875-16.2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Morrison B. M., Lachey J. L., Warsing L. C., Ting B. L., Pullen A. E., Underwood K. W., et al. (2009). A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 217 258–268. 10.1016/j.expneurol.2009.02.017 [DOI] [PubMed] [Google Scholar]
  35. Oliveira N. A. S., Pinho B. R., Oliveira J. M. A. (2023). Swimming against ALS: How to model disease in zebrafish for pathophysiological and behavioral studies. Neurosci. Biobehav. Rev. 148:105138. 10.1016/j.neubiorev.2023.105138 [DOI] [PubMed] [Google Scholar]
  36. Pansarasa O., Rossi D., Berardinelli A., Cereda C. (2014). Amyotrophic lateral sclerosis and skeletal muscle: An update. Mol. Neurobiol. 49 984–990. 10.1007/s12035-013-8578-4 [DOI] [PubMed] [Google Scholar]
  37. Paredes-Zúñiga S., Trost N., De la Paz J. F., Alcayaga J., Allende M. L. (2019). Behavioral effects of triadimefon in zebrafish are associated with alterations of the dopaminergic and serotonergic pathways. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 92 118–126. 10.1016/j.pnpbp.2018.12.012 [DOI] [PubMed] [Google Scholar]
  38. Peng D., Fu M., Wang M., Wei Y., Wei X. (2022). Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol. Cancer 21 1–20. 10.1186/s12943-022-01569-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Peters S., Zitzelsperger E., Kuespert S., Iberl S., Heydn R., Johannesen S., et al. (2017). The TGF-β system as a potential pathogenic player in disease modulation of amyotrophic lateral sclerosis. Front. Neurol. 8:669. 10.3389/fneur.2017.00669 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pradat P. F., Dubourg O., De Tapia M., Di Scala F., Dupuis L., Lenglet T., et al. (2011). Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener. Dis. 9 38–52. 10.1159/000329723 [DOI] [PubMed] [Google Scholar]
  41. Renton A. E., Chiò A., Traynor B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17 17–23. 10.1038/nn.3584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Riva N., Agosta F., Lunetta C., Filippi M., Quattrini A. (2016). Recent advances in amyotrophic lateral sclerosis. J. Neurol. 263 1241–1254. 10.1007/s00415-016-8091-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Robinson K. J., Yuan K. C., Don E. K., Hogan A. L., Winnick C. G., Tym M. C., et al. (2019). Motor neuron abnormalities correlate with impaired movement in zebrafish that express mutant superoxide dismutase 1. Zebrafish 16 8–14. 10.1089/zeb.2018.1588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rosen D. R., Siddique T., Patterson D., Figlewicz D. A., Sapp P., Hentati A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 59–62. 10.1038/362059a0 [DOI] [PubMed] [Google Scholar]
  45. Shefner J., Heiman-Patterson T., Pioro E. P., Wiedau-Pazos M., Liu S., Zhang J., et al. (2020). Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve 61 218–221. 10.1002/mus.26740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Si Y., Kim S., Cui X., Zheng L., Oh S. J., Anderson T., et al. (2015). Transforming growth factor beta (TGF-β) is a muscle biomarker of disease progression in ALS and correlates with smad expression. PLoS One 10:e0138425. 10.1371/journal.pone.0138425 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Simonetta S. H., Golombek D. A. (2007). An automated tracking system for Caenorhabditis elegans locomotor behavior and circadian studies application. J. Neurosci. Methods 161 273–280. 10.1016/j.jneumeth.2006.11.015 [DOI] [PubMed] [Google Scholar]
  48. Taylor J. P., Brown R. H., Cleveland D. W. (2016). Decoding ALS: From genes to mechanism. Nature 539 197–206. 10.1038/nature20413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Unsicker K., Flanders K. C., Cissel D. S., Lafyatis R., Sporn M. B. (1991). Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience 44 613–625. 10.1016/0306-4522(91)90082-Y [DOI] [PubMed] [Google Scholar]
  50. Vander Ark A., Cao J., Li X. (2018). TGF-β receptors: In and beyond TGF-β signaling. Cell. Signal. 52 112–120. 10.1016/j.cellsig.2018.09.002 [DOI] [PubMed] [Google Scholar]
  51. Vincze C., Pál G., Wappler E. A., Szabó ÉR., Nagy Z. G., Lovas G., et al. (2010). Distribution of mRNAs encoding transforming growth factors-β1,-2, and-3 in the intact rat brain and after experimentally induced focal ischemia. J. Comp. Neurol. 518 3752–3770. 10.1002/cne.22422 [DOI] [PubMed] [Google Scholar]
  52. Walton K. L., Johnson K. E., Harrison C. A. (2017). Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front. Pharmacol. 8:461. 10.3389/fphar.2017.00461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Witzel S., Maier A., Steinbach R., Grosskreutz J., Koch J. C., Sarikidi A., et al. (2022). Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 79:121. 10.1001/jamaneurol.2021.4893 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wong C. O., Venkatachalam K. (2019). Motor neurons from ALS patients with mutations in C9ORF72 and SOD1 exhibit distinct transcriptional landscapes. Hum. Mol. Genet. 28 2799–2810. 10.1093/hmg/ddz104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wynn T. A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. 214 199–210. 10.1002/path.2277 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Xing C., Gong B., Xue Y., Han Y., Wang Y., Meng A., et al. (2015). TGFβ1a regulates zebrafish posterior lateral line formation via Smad5 mediated pathway. J. Mol. Cell Biol. 7 48–61. 10.1093/jmcb/mjv004 [DOI] [PubMed] [Google Scholar]
  57. Zubiri I., Lombardi V., Bremang M., Mitra V., Nardo G., Adiutori R., et al. (2018). Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol. Neurodegener. 13 1–17. 10.1186/s13024-018-0292-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table_1.docx (15.7KB, docx)

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Cellular Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES